Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRLHR | P49683 | 6/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 4/20 | 0.34 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | GIPR | P48546 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | LSS | P48449 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24173968 | 0.94 | PRLHR (0.36) | PRLHRMAPK8MAPK10POLBMAPT | |
| SCHEMBL22845518 | 0.91 | PRLHR (0.35) | PRLHRPOLBMAPT | |
| SCHEMBL22845200 | 0.91 | GCGR (0.38) | PRLHRTRPV1POLBMAPTGCGR | |
| SCHEMBL22845208 | 0.90 | PRLHR (0.35) | PRLHRPOLBMAPTCYP2C9 | |
| SCHEMBL22845379 | 0.89 | PREP (0.36) | PRLHRPOLBMAPT | |
| SCHEMBL22845418 | 0.88 | PRLHR (0.34) | PRLHR | |
| SCHEMBL22845234 | 0.85 | PRLHR (0.34) | PRLHRPOLBMAPT | |
| SCHEMBL24483837 | 0.85 | GCGR (0.38) | PRLHRTRPV1POLBMAPTGCGR | |
| SCHEMBL22845527 | 0.85 | PREP (0.37) | PRLHRMAPK8MAPK10MAPT | |
| SCHEMBL22845325 | 0.85 | MAPT (0.41) | PRLHRMAPK8MAPK10POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | PRLHR 2579/4885MAPK8 1374/4885MAPK10 1272/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | PRLHR 2579/4885MAPK8 1374/4885MAPK10 1272/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | PRLHR 2579/4885MAPK8 1374/4885MAPK10 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.